MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo targets had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients,